Table 1.
Characteristics of 139 glioblastoma patients with FFPE tumor samples obtained at first surgery.
| All Patients N = 139 N (%) |
Patients without gene fusions by RNA-Seq N = 78 N (%) |
Patients with gene fusions by RNA-Seq N = 61 N (%) |
p* | |
|---|---|---|---|---|
| Median age, years (range) | 63.0 (54.5–70.0) | 62.0 (54.0–69.0) | 64.0 (55.0–71.0) | 0.242 |
| Age group | 1.000 | |||
| ≤ 65 years | 83 (59.7) | 47 (60.3) | 36 (59.0) | |
| > 65 years | 56 (40.3) | 31 (39.7) | 25 (41.0) | |
| Sex | 0.606 | |||
| Men | 82 (59.0) | 48 (61.5) | 34 (55.7) | |
| Women | 57 (41.0) | 30 (38.5) | 27 (44.3) | |
| Surgery | 0.429 | |||
| Unknown | 12 (8.63) | 7 (8.97) | 5 (8.20) | |
| Gross-total | 29 (20.9) | 19 (24.4) | 10 (16.4) | |
| Subtotal | 83 (59.7) | 42 (53.8) | 41 (67.2) | |
| Biopsy | 15 (10.8) | 10 (12.8) | 5 (8.20) | |
| MGMT methylation status | 0.011 | |||
| Unknown | 8 (5.76) | 3 (3.85) | 5 (8.20) | |
| Methylated | 68 (48.9) | 32 (41.0) | 36 (59.0) | |
| Unmethylated | 63 (45.3) | 43 (55.1) | 20 (32.8) | |
| G-CIMP | 0.002 | |||
| Unknown | 15 (10.8) | 14 (17.9) | 1 (1.6) | |
| No | 118 (84.9) | 60 (76.9) | 58 (95.1) | |
| Yes | 6 (4.32) | 4 (5.13) | 2 (3.3) | |
| TCGA subtype | < 0.001 | |||
| Unknown | 15 (10.8) | 14 (17.9) | 1 (1.6) | |
| Classical | 53 (38.1) | 22 (28.2) | 31 (50.9) | |
| Mesenchymal | 32 (23.0) | 24 (30.8) | 8 (13.1) | |
| Proneural | 39 (28.1) | 18 (23.1) | 21 (34.4) | |
| IGS_subtype | 0.001 | |||
| Unknown | 15 (10.8) | 14 (17.9) | 1 (1.64) | |
| IGS0 | 6 (4.32) | 4 (5.13) | 2 (3.28) | |
| IGS16 | 2 (1.44) | 2 (2.56) | 0 (0.00) | |
| IGS17 | 12 (8.63) | 7 (8.97) | 5 (8.20) | |
| IGS18 | 68 (48.9) | 32 (41.0) | 36 (59.0) | |
| IGS22 | 4 (2.88) | 2 (2.56) | 2 (3.28) | |
| IGS23 | 18 (12.9) | 14 (17.9) | 4 (6.56) | |
| IGS9 | 14 (10.1) | 3 (3.85) | 11 (18.0) | |
| IDH1 (by IHC) | 0.895 | |||
| Unknown | 12 (8.63) | 6 (7.69) | 6 (9.84) | |
| Negative | 122 (87.8) | 69 (88.5) | 53 (86.9) | |
| Mutated | 5 (3.60) | 3 (3.85) | 2 (3.28) | |
| Long survival | ||||
| ≤ 30 months | 115 (82.7) | 67 (85.9) | 48 (78.7) | 0.374 |
| > 30 months | 24 (17.3) | 11 (14.1) | 13 (21.3) | |
MGMT O-6-methylguanine-DNA methyltransferase, TCGA the cancer genome atlas, IGS intrinsic gene expression subtypes, IHC immunohistochemistry, G-CIMP glioma CpG island methylator phenotype.
*p-value for comparison between patients with and without gene fusions in their tumor samples.